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VASOPROTECTION BY NO: 
eNOS AS A NOVEL THERAPEUTIC TARGET
Over the last two decades, it has become evident that the
endothelium is not merely an inert, single-cell lining that covers
the internal surface of blood vessels, but in fact plays a crucial
role in regulating vascular function. Although serving as an
extremely active endocrine and paracrine organ that produces a
large variety of molecules participating in complex biochemical
processes, the simple product generated by endothelial nitric
oxide synthase (eNOS) - nitric oxide (NO) - seems to be the key
molecule required for the maintenance of vascular homeostasis
(1-4). For example, NO produced by eNOS causes vasodilation.
Thus, eNOS knockout mice are hypertensive (5), whereas eNOS
transgenic mice exhibit hypotension (6). In addition, NO reduces
the activation and aggregation of platelets, attenuates adhesion of
leukocytes to the endothelium, reduces the permeability of the
endothelium, and inhibits proliferation and migration of vascular
smooth muscle cells. Impaired activity of eNOS and the loss of
NO bioavailability are associated with endothelial cell
dysfunction that is itself an independent risk factor for
cardiovascular diseases (2, 3). Several factors contribute to loss
of NO bioavailability, including reduced NO synthesis and NO
scavenging O2-. Under physiological conditions, there is a
balance between endothelial NO and O2- production. However,
vascular diseases are associated with increased O2- generation,
and several oxidase systems contribute to increased oxidative
stress, notably NADPH-dependent oxidases and eNOS itself (1).
Under oxidant stress, production of O2- and its derived oxidants,
including peroxynitrite (ONOO-), induce eNOS dysfunction with
uncoupling of the enzyme leading to the production of NOS-
derived O2- instead of NO. It has been shown that an imbalance
between NO and O2- can contribute to the onset of a variety of
cardiovascular disease states such as atherosclerosis, thrombosis,
hypertension, diabetes mellitus, heart failure, post-angioplasty
restenosis, cerebral vasospasm and delayed wound healing (2, 3).
Therefore, tight coupling of the enzyme is important for normal
cardiovascular function and thus prevention of disease onset.
Regulation of eNOS coupling
The catalytic domains of NOS include a flavin-containing
NADPH binding reductase and a heme-binding oxygenase, that
also contains the binding site labile cofactor tetrahydrobiopterin
JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2009, 60, Suppl 4, 83-93
www.jpp.krakow.pl
L.W. DOBRUCKI1, B.J. MARSH2,3,4,5, L. KALINOWSKI6
ELUCIDATING STRUCTURE-FUNCTION RELATIONSHIPS FROM MOLECULE-TO-CELL-
TO-TISSUE: FROM RESEARCH MODALITIES TO CLINICAL REALITIES
1Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven,
Connecticut, U.S.A.; 2Institute for Molecular Bioscience, 3Centre for Microscopy and Microanalysis, 
4ARC Centre of Excellence in Bioinformatics St Lucia, Australia; 5School of Chemistry and Molecular Biosciences, 
The University of Queensland, St Lucia, Australia; 6Department of Medical Laboratory Diagnostics, 
Chair of Clinical Chemistry and Biochemistry, Medical University of Gdansk, Gdansk, Poland
The National Academy of Engineering selected ‘Imaging’ as one of the greatest engineering achievements of the 20th
century (Greatest Engineering Achievements of the 20th Century. 2009 (cited 2008, November 10); available from:
http://www.greatachievements.org/). The combination of different imaging modalities and technologies for mapping
bimolecular and/or biological processes within single cells or even whole organs has extraordinary potential for
revolutionizing the diagnosis and treatment of pathophysiological disorders, and thus for mitigating the significant social
and economic costs associated with the clinical management of disease. Such integrated imaging approaches will
eventually lead to individualized programs for disease prevention through advanced diagnosis, risk stratification and
targeted cell therapies resulting in more successful and efficient health care. The goal of this article is to provide readers
with a current update of selected of state-of-the-art imaging modalities which would likely to lead to improved clinical
outcomes if employed in an integrated approach, including use of ultramicrosensors to detect reactive oxygen/nitrogen
species in a single cell, use of electron tomography to visualize and characterize cellular organization in three
dimensions (3D), and molecular imaging strategies to assess naturally occurring and therapeutic peripheral and
myocardial angiogenesis using targeted radiolabeled tracers.
K e y  w o r d s :  biosensors, nitric oxide, superoxide, peroxynitrite, endothelium, endothelial nitric oxide synthase, cellular
tomography, electron microscope tomography, 3D reconstruction, mammalian, insulin, secretion, beta cell, islets
of Langerhans, angiogenesis, imaging of angiogenesis, integrins, single photon emission computed tomography,
positron emission tomography
(BH4) and the substrate L-arginine (1, 7). In the presence of Ca2+
and calmodulin, electrons flow from NADPH through the
reductase domain to the oxygenase domain resulting in the
activation of oxygen at the heme center followed by the substrate
monooxygenation. This process requires the presence of the
fully reduced BH4 and appropriate L-arginine availability. One
of the primary mechanisms implicated in the oxidant-induced
switch of eNOS from the production of NO to the generation of
O2- is the oxidation of the enzyme-bound BH4 and/or disruption
of the zinc-thiolate complex.
Various extracellular signals, including shear stress and
additional stimuli such acetylcholine, bradykinin, vascular
endothelial growth factor (VEGF), estrogen, sphingosine 1-
phosphate and aldosterone, modulate eNOS-derived NO
generation through several transduction pathways. Cellular
studies have demonstrated that phosphorylation of eNOS at
specific amino acids regulates enzyme-mediated NO production
(8). With this line, it has been reported that protein kinase B
(Akt) specifically induces phosphorylation of Ser-1177 and
protein kinase C specifically phosphorylates Thr-495. Although
phosphorylation of Ser-1177 has been shown to increase NO
production from eNOS (9), in contrast, phosphorylation of Thr-
495, has been demonstrated to down-regulate NO generation
(10, 11). Furthermore, other studies have revealed that
phosphorylation can regulate O2- in addition to NO generation
from eNOS (12). It has been shown that phosphorylation of Ser-
1177 greatly increases O2- generation, by altering both the Ca2+
sensitivity of the enzyme and the rate of product formation,
toward eNOS-dependent O2- generation becoming largely Ca2+-
independent. Thr-495 phosphorylation, in turn, indirectly
regulates eNOS function through regulation of the calmodulin
and caveolin interaction, but this is not necessarily associated
with a decrease in eNOS-dependent O2- formation.
It should be noted that O2- reacts rapidly with NO to form
ONOO-, which is a strong biological oxidant known to oxidize
lipids, proteins, sylfhydryls, and DNA and to cause nitration of
tyrosines (13). On the one hand, it has been suggested that
ONOO- uncouples eNOS by oxidation of the zinc-thiolate
complex that comprises the BH4 binding site; this in turn leads
to dissociation of eNOS dimers to monomers (14). On the other
hand, it has been suggested that BH4 per se is an important target
for oxidation by ONOO- (15, 16). Of note, ONOO- is more
potent than either O2- or H2O2 in causing oxidation of BH4 (15,
17, 18). It has been shown that treatment of purified eNOS with
ONOO- significantly decreased the ability of the enzyme to
produce NO. Furthermore, ONOO- strikingly increased vascular
O2- production in vessels from control mice but not in vessels
from eNOS-deficient mice, suggesting that eNOS was the source
of O2- (17). Thus, it is possible that both the zinc-thiolate center
and BH4 are targets of oxidation by ONOO-, particularly when
high levels of this oxidant are present.
Evaluation of eNOS activity: biosensors for concurrent
detection of NO, O2- and ONOO-
Given the beneficial effects of endothelial NO, an increase of
eNOS activity by pharmacological means or (local) gene therapy,
could be possibly beneficial in patients at increased risk of
cardiovascular diseases. However, eNOS-derived NO also has
detrimental effects, such as the generation of O2-, making it
difficult to predict whether increased eNOS activity is beneficial
of harmful. To determine whether increased eNOS activity may be
beneficial, we have generated ultramicrosensors for NO, O2- and
ONOO-, combined into one working unit, which allow us to
measure concurrently NO, O2- and ONOO- concentrations in real
time in a single cell (Fig. 1). Each microsensor was made by
electroplating a sensing material, a specific polymeric complexes
with metalloporphyrin or enzyme, on the tip of carbon fiber
(length 1 mm, diameter 0.5 µm) to facilitate the electron transfer
on or from the detected molecule to the sensor (Fig. 2). The fibers
were sealed with nonconductive epoxy and electrically connected
to copper wires with conductive silver epoxy. The following
conductive polymeric films were applied: nickel(II)tetrakis (3-
methoxy-4-hydroxyphenyl) porphyrin for the sensor of NO, an
immobilized polypyrrole/horseradish peroxidase (PPy/HRP) for
the sensor of O2- and manganese(III)-[2,2]paracyclophany-
lporphyrin for the sensor of ONOO-. In addition, the sensors for
NO and ONOO- were supercoated with a negatively charged
polymer (nafion) for NO sensor or positively charged dopamine
for ONOO- sensor that repelled or retarded charged species while
allowing NO or ONOO- access to the underlying catalytic surface.
A three-electrode system, which includes the tandem NO, O2-,
ONOO -sensors as a working electrode, counter platinum
electrode, and calomel reference electrode, was used with constant
potentials of 0.65 V for NO detection, -0.45 V for ONOO-
detection and -0.23 V for O2- detection. The system was coupled
with potentiostat (e.g. Gamry Reference 600 multichannel) and
personal computer with electrochemical software (e.g. VFP600,
Gamry Instruments, Warminster, PA, USA). The tandem sensors
are highly sensitive for NO, O2-, ONOO- (10-9 mol/L detection
limit for each sensor), and their response time is rapid (on the
order of 10-4 s each), providing the ability to make kinetic
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Fig. 1. Typical amperogram curves showing kinetics of nitric oxide
(NO) (A), superoxide (O2-) (B), and peroxynitrite (ONOO-) (C)
release from a single endothelial cell after endothelial nitric oxide
synthase (eNOS) stimulation. eNOS was stimulated with 1 µmol/L
calcium ionophore (CaI; A23187). The experiments were made on
the endothelium obtained from aortic rings isolated from normal
rats. While considering the effect of potent eNOS agonists, it
should be born in mind that activation of NO release by any eNOS
agonists species in endothelial cells is always associated with
increase release of both O2- and ONOO-. Therefore, measurement
of NO/O2-/ONOO- ratio in the timecourse of action of a vasoactive
agent is an especially valuable approach for estimation of its
therapeutic benefits.
measurements of the detected molecules concentrations. The
active tips of the sensors system were maintained close to the
surface of a single endothelial cell with help of computer-
controlled micromanipulator.
Until the electrochemical concurrent measurements of NO,
O2-, ONOO- were applied in situ by using the ultramicrosensors,
it was totally unclear whether O2- production by dysfunctional
eNOS occurs only under specific pathological conditions or
whether it also occurs to some extent in normal endothelium that
is not exposed to cardiovascular risk factors. We have shown for
the first time that these mechanisms tightly regulate the delicate
balance between NO, O2- and ONOO- at different redox levels
within native endothelial cells, and may thus help to explain why
some individuals seem predisposed to endothelial vasodilator
dysfunction (19). Application of these sensors in our studies
enabled us to demonstrate that the steady state of NO, O2- and
ONOO- balance within endothelial cells can be modified by
pharmacological intervention (19-26). We provided direct
evidence that some drugs are potent in terms of their capacity to
increase NO bioavailability in endothelial cells through
preservation of eNOS function, and may have clinical
application for either the prevention of endothelial dysfunction
(by preservation of eNOS coupling) or the restoration of
endothelial dysfunction (by reversal of eNOS uncoupling).
These novel pharmacological properties associated with an
increase of NO bioavailability are revealed by the well-known
drugs (such as HMG-CoA reductase inhibitors and furopirydine
derivative cicletanine) as well as an endogenous compound, 1-
methylnicotinamide, a primary metabolite of nicotinamide, that
until recently was thought to be biologically inactive (Fig. 3).
In conclusion, although eNOS has been suggested as a
potential target for treatment in human endothelium, upregulation
of eNOS function might not always be good. eNOS uncoupling
seems to be present in numerous common diseases, as well as in
native endothelial cells of healthy humans. This is an important
caveat for clinical strategies aimed at pharmacological
intervention to target eNOS activity or eNOS expression, since
enzyme upregulation might even aggravate vascular damage in
such cases. The net effect of the reaction between NO and O2-
compromises reduction of concentration of both products as well
as the biological effects of ONOO- itself. Thus, increased
production of a deleterious metabolite, ONOO-, by eNOS, may
shift the balance between oxidative and reductive states of the
endothelial cell (towards nitroxidative stress) and may alter the
beneficial effects of increased NO activity. Detection of NO
together with concurrent detection of O2- and ONOO-, localized to
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Fig. 2. A maximal nitric oxide (NO) (A), superoxide (O2-) (B), and peroxynitrite (ONOO-) (C) concentrations produced by the
endothelial cells (rat aorta) in the presence of 300 µmol/L NG-nitro-L-arginine methyl ester (L-NAME), 1 µmol/L simvastatin (Sim),
1 µmol/L cicletanine (Cic; (±)3-(4chlorophenyl)-1,3-dihydro-7-hydroxy-6-methylfuro-[3,4-c] pyridine) 3-(4-chlorophenyl)-1,3-
dihydro-7-hydroxy-6-methylfuro-[3,4-c] pyridine) or 1 µmol/L 1-methylnicotinamide (MNA+). The ratio of NO concentration to the
ONOO- concentration represents the index of nitroxidative stress (D); higher [NO/ONOO-] indicates stronger eNOS coupling and
greater bioavailability of NO within the cells. The aortic rings isolated from normal rats were incubated in the incubation chamber for
30 minutes with the tested substance prior to CaI addition. Inhibition of NO production by L-NAME with concurrent inhibition of O2
and ONOO- formation during activation of eNOS supports the concept that uncoupling of eNOS occurs in intact endothelial cells.
Among the tested substances, the action of cicletanine followed by simvastatin and 1-methylnicotinamide demonstrates the most
favorable potency toward the restoration of the disturbed eNOS-dependent NO/O2-/ONOO- balance after maximal stimulation of the
enzyme by CaI. *P<0.01 and **P<0.001 vs. CaI alone (C), n = 5-6 experiments. The data are presented as means ±SE. Multiple
comparisons were evaluated using ANOVA followed by the Student’s test.
the vicinity of eNOS in operation (surface of the cell membrane),
offers the advantage of for precisely evaluating the extent of
eNOS uncoupling,, since the measurements are made in situ in
real time, and in the location with the highest concentrations of the
detected molecules. Consequently, this approach affords the most
efficient and accurate means for testing compounds that may
potentially have beneficial effects by targeting the endothelium for
improved eNOS function and nitroxidative stress.
3D ELECTRON MICROSCOPY OF MAMMALIAN CELLS
AND TISSUES
Since the first images of cultured mammalian cells taken on
an electron microscope (EM) by Albert Claude, Ernest Fullam and
Keith Porter were published in the United States in 1945 (27), the
ultrastructural analysis of mammalian cells and tissue has relied
almost entirely on the interpretation of two-dimensional (2D)
images to deduce the three-dimensionality of the organelles, cells
and/or tissue under study. However, over the past decade, electron
microscope tomography (ET) - also often referred to as ‘electron
tomography’ or ‘cellular tomography’ - has emerged as a powerful
research tool for studying mammalian cell and tissue biology in
3D in situ, in an appropriate physiological context (28-33). ET
uses mathematical techniques to computationally reconstruct a 3D
volume from a set of accurately aligned 2D images, in a manner
similar to clinical/diagnostic 3D imaging techniques such as
computed tomography (CT), magnetic resonance imaging (MRI)
and positron emission tomography (PET), as discussed in more
detail elsewhere in this article (34). However, rather than
computing a 3D reconstruction of a patient’s (or an animal’s)
anatomy, a 3D snapshot revealing a cell’s anatomy is produced,
but at approximately 105-106 times higher resolution (i.e. ~5 nm)
than for our clinical imaging counterparts listed above (35-37).
Methods
Ideally, high resolution cellular imaging studies by ET are
undertaken on tissue prepared using advanced cryo-preparation
techniques so that the physiological state and architecture of the
cell(s) of interest is captured as reliably as possible (38-41), with
the obvious exception of cases where the physiology and/or
physical location of the tissue under study makes this impractical
(42). By stopping all cellular processes in a matter of milliseconds
using a ‘fast-freezing’ approach, delicate structures and dynamic
events are immobilized in a ‘close-to-native’ state (43, 44).
Typically, such ‘frozen-hydrated’ cells are then processed for EM
at ultra-low temperatures using a method called ‘freeze-
substitution’, and are subsequently infiltrated with resin. After
plastic-embedding, the tissue is sliced into sequential slabs called
‘sections’, each about 250-400 nm thick, which can be viewed and
imaged either individually or in series (38, 39). Thick sections are
cut rather than conventional thin (60-100 nm) sections in order to
visualize as much of the depth of the specimen as quickly as
possible as well as minimize disruption of the tissue by reducing
the number of times the specimen has to be physically cut or
‘sectioned’. It is worth noting that many dozens of such serial
‘thick’ sections are needed to span the entire volume of a single
mammalian cell (45). 2D images are then collected in an EM that
operates at higher-than-normal voltages (e.g. ≥300 keV compared
to conventional EMs that operate in the range of 80-120 keV), as
the section is serially tilted by small, regular increments (e.g. 1° or
1.5°) over a relatively large angular tilt range (e.g. ±60-70°). These
sets of images – referred to as a ‘tilt series’ - are initially aligned
with one another using a mathematical technique called ‘cross-
correlation’, which uses information common within each image
to bring the tilt series images crudely into register. The images are
then aligned more accurately by precisely tracking the positions of
small gold fiducial markers placed on the top and bottom of each
section prior to imaging in the EM, and a 3D density distribution
or ‘tomogram’ is computed from each set of aligned tilts around a
single-axis using another mathematical technique referred to as
‘weighted back-projection’ (30). However, for cellular
tomography, tilt series data are preferentially collected around two
orthogonal axes rather than just a single axis because the
resolution of an object within the plane of a specimen that has a
slab geometry - such as a thick slice (i.e. ‘section’) cut from
plastic-embedded cells and/or tissue - also depends on its
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Fig 3. A cyclic reaction mechanism
during the signal transduction (from
chemical into electrical) by the sensing
material (the complexes of organic
polymers with metal ions) of nitric oxide
(NO) sensor (A), superoxide (O2-) sensor
(B) and peroxynitrite (ONOO-) sensor
(C). HRPred, HRPox – reduced and
oxidized forms of horseradish peroxidase,
respectively; Ni+2/Ni+3-Poly-Porphyrin –
poly-nickel(II/III) tetrakis(3-methoxy-4-
hydroxyphenyl) porphyrin; Os+2/Os+3-
Poly-EA-PEGDE-HRP – complexes of
cis-[osmium(II/III)(bpy)2 Cl2]-[poly(4-
vinyl-pyridine)] and poly (ethylene
glycol)diglycidyl ether and horseradish
peroxidase; Mn+3/Mn+4-Poly-Porphyrin –
poly-manganese(III/IV)-[2,2]paracyclo-
phanylporphyrin.
orientation relative to the axis around which the specimen is tilted.
In this case, individual tomograms generated for each axis are
brought into register and then combined in 3D to produce a dual-
axis reconstruction that exhibits improved symmetry and
resolution in all three dimensions.
However, due to the scale and complexity of the image data
that are represented in 3D reconstructions of cellular volumes
generated using this approach, detailed image
segmentation/analysis is necessary before meaningful biological
insights can be made. However, once segmented and meshed,
not only can organelles and other structures (e.g. ribosomes and
microtubules) be viewed unambiguously in 3D either alone or in
context with any other object(s) or combination of object(s), but
precise quantitative measurements (e.g. membrane surface area
and volume) can be obtained relatively quickly using the
triangular mesh information for each object. Unfortunately,
however, due to the relatively low signal-to-noise ratio (from a
mathematical perspective) that is characteristic for these kinds of
EM data, most automated/algorithmic segmentation approaches
have to date yielded poor results. Instead, cellular tomograms
must be painstakingly segmented by manually outlining the
membrane boundaries of objects of interest on each pixel-thick
tomographic slice using drawing tools available in software
analysis packages specialized for complex 3D biological image
data such as IMOD (46), in order to build up a ‘contour map’ in
the Z dimension from which a 3D surface can be generated for
subsequent visualization and morphometric analysis.
Consequently, image segmentation represents the major ‘rate-
limiting step’ for ongoing discovery through a 3D ‘cell mapping’
approach to elucidating cellular function.
Outcomes
High resolution tomograms of large cellular volumes generated
and analyzed in this way have already provided fundamental new
insights at a number of levels regarding key structure-function
relationships among organelles of the insulin biosynthetic pathway,
including the identification of novel connections between
compartments within the Golgi complex that are normally
spatially/functionally distinct, leading to further debate related to
the potential role for direct connections in intra-Golgi transport (28,
39-41, 47, 48). Perhaps the most surprising insight afforded by
detailed analysis and segmentation of cellular tomograms has been
with regard to the degree of 3D spatial and structural complexity at
the subcellular level in the cytoplasm of mammalian cells (32, 49-
52) (Fig. 4). Indeed, the datasets provided through detailed studies
of cellular organization using 3D imaging methods such as ET
have attracted considerable attention from within the systems
biology and bioinformatics communities due to the significant
advantages they would confer by serving as precise (i.e. nanometer
scale) spatial/structural frameworks for more advanced
computational studies aimed at recreating and exploring
fundamental cellular processes and biophysical principles in silico,
from a mathematical/engineering perspective (51, 53, 54).
More recently, to both complement and extend the basic
insights derived through high resolution tomography of large
cellular volumes (such as those highlighted briefly above), and to
move toward a more integrated or ‘holistic’ approach to
understanding the mammalian cell as a prime example of an
ordered complex system (52), we have pioneered an approach for
imaging and reconstructing mammalian cells (in our case,
insulin-secreting beta cells) in their entirety in 3D at intermediate
(10-20 nm) resolution. These efforts were driven by the fact that
each of our high resolution tomograms constitutes just a narrow
cross-sectional ‘slab’ sliced from a mammalian cell, and typically
represents ≤1% of the total cell volume. The ‘expedited’ approach
we have developed yields fully annotated 3D reconstructions of
whole cells at ~10 nm resolution within just a few months, partly
due to the fact that we have developed new computational tools
in parallel that allow us to more efficiently annotate cellular
compartments and organelles of interest within the volume (45)
(Fig. 4). Notably, these new methods have allowed us to quantify
subtle changes in mitochondrial structure and organization
(number, length, extent of branching/fission/fusion) that reflect
the increased energy needs of the beta cell associated with
glucose-stimulated insulin biosynthesis and secretory granule
exocytosis. We are currently employing this comparative ‘whole
cell mapping’ approach to carry out more detailed investigations
aimed at precisely characterizing the nature of the changes that
occur at the level of inter-organellar relationships among the key
compartments involved in insulin synthesis and release.
Conclusions and future direction
Elucidating the 3D structural organization of molecules,
cells and tissues is pivotal to the development of a complete
understanding of basic cell and molecular biology, and thus
essential to successfully translating that knowledge to improved
therapeutic interventions for the prevention and/or treatment of
chronic diseases such as diabetes and cancer. High resolution 3D
imaging studies of insulin-secreting cells within pancreatic islets
have already provided new and unanticipated insights into the
complexity of 3D cellular organization that have impacted upon
how scientists, students and the public alike picture life at the
subcellular level. If current efforts are successful with respect to
integrating data related to the 3D structure-function relationships
that underpin intra- and inter-cellular interactions, networks and
signaling - from molecule-to-cell and from cell-to-tissue – next-
generation biologists and clinicians alike will benefit from a
more coherent understanding of molecular biology and
biochemistry in situ.
MOLECULAR TARGETED IMAGING OF ANGIOGENESIS
Angiogenesis represents a complex process of sprouting new
capillaries from preexisting vessels and plays an important role
in many human diseases such as cancer, coronary artery disease
(CAD), diabetes, atherosclerosis, and peripheral artery disease
(PAD) (55). The hypoxia-induced angiogenic process initiated
by expression of hypoxia-inducible factor 1 (HIF-1α) involves a
cascade of events including degradation of the extracellular
matrix (ECM) by matrix metalloproteinases (MMPs),
proliferation and migration of both smooth muscle and
endothelial cells, and the alignment of endothelial cells to form
tubes. A number of local and circulating angiogenic factors is
involved in this process including vascular endothelial growth
factor (VEGF), insulin-like growth factor (IGF-1),
angiopoietins, basic fibroblast growth factor (bFGF), and
endothelial adhesion molecules – integrins (55, 56).
In a cardiovascular setting the consequence of naturally
occurring angiogenesis triggered by hypoxic insult is the
restoration of perfusion and oxygenation of ischemic tissues.
This process has been traditionally assessed by evaluation of
perfusion, function and metabolism (57, 58), however more
recently molecular events associated with angiogenesis are
studied using novel noninvasive molecular targeted imaging
approaches (34, 58-65).
Molecular targeted imaging defined as in vivo qualitative or
quantitative characterization of biological processes at the
cellular, molecular, and whole body level has several
requirements; choice of molecular target, choice of probe, and
selection of imaging technology. Historically, the earliest
targeted imaging approaches utilizing a direct probe-target
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Fig 4. Example of the 3D spatial complexity of cellular organization as visualized by electron microscope tomography. With a view
to identifying how and where defects can occur as insulin is trafficked along compartments of the regulated secretory pathway after
synthesis in the endoplasmic reticulum (ER), we have developed and employed new imaging and computational approaches for
mapping beta cell biology in 3D at high resolution, first for cell culture models for insulin secretion (39) (A and B), then for beta cells
preserved in situ in pancreatic islet tissue isolated from mice (41, 45) (C and D) and humans. (A) A magnified view from part of a
single pixel-thick image slice extracted from the 315 slices that together comprised the high resolution (~6 nm) 3D reconstruction (3.1
x 3.2 x 1.2 µm3), which was estimated to represent approximately 1% of that cell’s total volume. The center of the region reveals the
stacked membranes of the Golgi complex in an insulin-secreting pancreatic beta cell (reproduced from data originally published in:
‘Organellar relationships in the Golgi region of the pancreatic beta cell line, HIT-T15, visualized by high resolution electron
tomography’ (39)). Each individual compartment was ‘segmented’ by manually tracing along the compartment’s bounding membrane
across each/every tomographic slice that the object spanned in Z through the volume using the IMOD software package (46) in order
to precisely define each spatially distinct compartment as a separate object within the tomogram. (B) Contours belonging to the same
surface were then meshed (in a manner akin to computer graphic animation) such that objects could be (1.) visualized in 3D, and (2.)
quantitative data computed for basic morphometric parameters (e.g. surface area and volume) using the triangular mesh data for the
objects. In the example shown here, the stacked membranes (i.e. ‘cisternae’) of the Golgi complex are displayed in the context of all
other neighboring organelles, vesicles, ribosomes and microtubules in the region. Color-coding: Golgi cisternae (cis-trans): light blue,
pink, cherry, green, dark blue, gold, red), endoplasmic reticulum (yellow), membrane-bound ribosomes (blue), free ribosomes
(orange), microtubules (bright green), insulin granules (blue), clathrin-negative vesicles (white), clathrin-positive compartments and
vesicles (red), clathrin-negative compartments/vesicles (purple) and mitochondria (dark green). Scale Bar, 500 nm. (C) A digital slice
(in the XY plane) extracted from a cellular tomogram of an islet beta cell reconstructed in toto in 3D at ~15 nm resolution. The boxed
area (inset) reveals the relative clarity of Golgi membranes for comparison with the higher resolution data shown in (A). (D) The
distribution of the 8250 mature (dark blue) and 520 immature (light blue) insulin granules within the cellular volume that corresponds
to the image slice data presented in (C) are revealed [reproduced from data originally published in: ‘Expedited approaches to whole
cell electron tomography and organelle mark-up in situ in high-pressure frozen pancreatic islets’ (45). Scale Bar, 1000 nm.
interaction concept involved native antibodies, which suffered
from high background activity and long clearance times. These
undesired characteristics were eliminated by using engineered
antibodies and peptide or peptidomimetic probes for imaging of
cell-specific antigens. However this direct imaging approach
requires a synthesis of a customized probe for every target of
interests. To overcome this limitation, indirect imaging
approaches were proposed including reporter gene technology,
which involves introduction of a reporter gene into cell nuclei
and detection of the reporter protein by using radioactive ligands
or reporter protein-specific probes. This complex technique was
described in detail in previous reviews (34, 65, 66).
The selection of an appropriate molecular target which
represents the process to be studied, and the selection of probe
which should have high affinity towards the molecular target are
critical to the specificity of any imaging approach. On the other
hand, imaging technology should provide the best combination
of sensitivity and both temporal and spatial resolution.
During recent decades a number of novel imaging modalities
and new high-sensitivity and high-resolution imaging systems
have been developed, however only a few are available for a
broad use in molecular imaging. True multidimensional nuclear
techniques such as single photon emission computed tomography
(SPECT) and positron emission tomography (PET) using beta-,
gamma- or positron-emitting radioisotopes are particularly well
suited for in vivo molecular imaging due to high sensitivity
(picomolar), spatial resolution (submillimeter-to-millimeter), and
availability of SPECT, PET scanners and molecular probes. Both
modalities present distinct advantages, but also suffer from
disadvantages based on the physical and chemical characteristics
described in detail elsewhere (67-69), therefore the decision
which technique to use should be based on the assessment of the
biological system to be studied, availability of radiolabeled
molecular probes, and accessibility to the instrumentation.
Recent clinical trials of stimulated angiogenesis in CAD and
PAD to induce new blood vessel growth and thereby improve
perfusion, tissue oxygenation, substrate exchange, and function,
demonstrated no clear benefit over placebo, despite positive results
in animal studies (70-76). The evaluation of therapeutic
angiogenesis in these trials has focused on a number of clinical
endpoints such as exercise tolerance, quality of life, and survival.
Therefore there is a need to develop noninvasive approaches for
direct evaluation of the molecular events associated with
angiogenesis by use of direct biologic markers of the angiogenic
process. Potential biologic targets for imaging angiogenesis were
identified by the panel of the American Society of Nuclear
Cardiology experts during Invitation Meeting in Lake Tahoe in
2002 (77). Among other recommendations, in particular VEGF,
VEGF receptors, and integrins have been identified as favorable
targets for imaging angiogenesis which put focus on the
development of nuclear probes for these specific targets. The
potential for targeted imaging of the αvβ3 integrin and VEGF
receptors has been demonstrated in animal models of ischemia-
induced peripheral and myocardial angiogenesis as outlined below.
VEGF121 isoform was used as a targeting ligand for both
SPECT and PET studies to assess angiogenic process by imaging
VEGF receptor in animal models of both tumor and ischemia-
induced peripheral and myocardial angiogenesis (60, 64, 78). Initial
studies involved 111Indium labeled VEGF121 for SPECT imaging of
angiogenesis in a rabbit model of hindlimb ischemia (78). A few
years later Cai et al. successfully identified angiogenic tumor
vasculature in mice using positron-emitting 64Cu-labeled VEGF121
(60). More recently the same group developed a PET tracer, 64Cu-6-
DOTA-VEGF121, which was used to image myocardial
angiogenesis in rats at various time points post myocardial
infarction induced by the left coronary artery ligation (64). This
study demonstrated that 64Cu-6-DOTA-VEGF121 preferentially
localized in the infarct region with the maximum radiotracer uptake
at day 3 post myocardial infarction which was validated by
immunohistochemistry of VEGF receptor expression. Other groups
developed cardiac-specific reporter as a gene expression system to
be used in PET imaging of VEGF receptor in rats (79) and porcine
myocardium following adenoviral transfer (80).
The integrins, a family of endothelial cell membrane
receptors which serve as adhesion proteins, are involved in a
number of cellular processes including angiogenesis. Particularly
αvβ3 integrin containing RGD (Arg-Gly-Asp) motif is
abundantly expressed on proliferating endothelial cells and is
required for angiogenesis-associated cellular processes including
endothelial cell migration. Multiple groups of investigators
proposed using αvβ3 integrin as a potential target for imaging
angiogenesis. The earliest studies were focused on tumor
angiogenesis and involved using human monoclonal antibody
(LM609) for in vivo magnetic resonance imaging of angiogenesis.
This approach suffered from slow clearance rate of the antibody,
therefore more recently new RGD peptides with high affinity for
αvβ3 integrin have been identified and successfully used for
imaging angiogenesis (58, 81). The phage-display screening
identified the cyclo-(Arg-Gly-Asp-D-Phe-Val) which
demonstrated a potent inhibitory activity towards αvβ3 integrin
and was used for SPECT and PET imaging of tumor-associated
angiogenesis (82-85). Others evaluated an 111In-labeled quinolone
(RP748) for noninvasive assessment of myocardial angiogenesis.
Meoli et al. reported successful application of RP748 for imaging
myocardial angiogenesis in rats and dogs after myocardial
infarction (86). RP748 uptake localized in the infarct regions and
was associated with increased expression and activity of αvβ3
integrin in hypoperfused myocardial segments. More recently,
Kalinowski et al. demonstrated the relationship between RP748,
myocardial perfusion (assessed with 99mTc-sestamibi) and hypoxia
(assessed with 99mTc-labeled nitroimidazole) in rodent and canine
models of myocardial ischemia (87). Other groups evaluated
RGD-containing peptide 99mTc-NC100692 for imaging
myocardial and peripheral angiogenesis in animal models of CAD
and PAD. Initial reports demonstrated efficacy, safety, metabolic
stability and favorable biodistribution of the radiotracer (88-90).
Hua et al. demonstrated that NC100692 preferentially localized
within the ischemic hindlimb after ligation of the right femoral
artery in mice. High resolution planar SPECT image analysis was
validated with gamma well counting of muscle tissues indicating
NC100692 maximal uptake at 1 week after the surgery in consent
with increase in capillary density assessed by
immunohistochemistry (61). Shortly after this initial report,
NC100692 was used to assess myocardial angiogenesis in mice
lacking matrix metalloproteinase MMP-9 (62) and in rats
subjected to intramyocardial insulin-like growth factor (IGF-1)
gene transfer after myocardial infarction (91).
With the availability of dedicated hybrid small animal
microSPECT-CT and microPET-CT scanners it become possible
not only to localize radiotracer uptake with help of reference CT
image (Fig. 5, 6A) but also to develop novel approaches to
quantify microSPECT or microPET images acquired serially at
various time points (Fig. 6B) (92). Using irregular regions-of-
interests (ROIs) defined on CT reference image to quantify
NC100692 uptake within the ischemic hindlimb, Dobrucki et al.
demonstrated that mice lacking the gene for endothelial nitric
oxide synthase (eNOS) have impaired peripheral angiogenesis
(92-94). Similar observations were made in diabetic mice
subjected to femoral artery occlusion (95).
To complement the strengths of PET (sensitivity) and
SPECT (resolution) imaging, few groups put effort at design and
development of bifunctional multimeric RGD peptides for
SPECT and PET imaging of angiogenesis by incorporating both
99mTc and 64Cu radioisotope, respectively (96). More recent
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Fig. 5. Representative in vivo short axis (SA),
vertical long axis (VLA) and horizontal long
axis (HLA) X-ray CT, 99mTc-NC100692 and
201Tl chloride images from C57BL6 mouse at 1
week after myocardial infarction. 99mTc-
NC100692 images were registered with 201Tl
chloride perfusion images and X-ray CT images
to better demonstrate localization of 99mTc-
NC100692 activity within the heart. Arrows on
201Tl chloride images indicate the regions of
perfusion defect (infarct). This corresponds to
the regions of increased 99mTc-NC100692
activity in the anterior wall of infarcted heart.
The images were acquired with dedicated small
animal hybrid microSPECT-CT scanner (X-
FLEX, GE Healthcare).
Fig. 6. Representative hybrid microSPECT-CT
99mTc-NC100692 images of peripheral angiogenesis
in murine model of hindlimb ischemia. (A)
microCT images of bone structures and skin were
registered with microSPECT images of 99mTc-
NC100692 targeted at αvβ3 integrin to better
demonstrate localization of the radiotracer within
ischemic hindlimb marked by yellow arrows. (B)
microCT images can be also used to quantify
radiotracer uptake in soft tissues within ischemic or
nonischemic hindlimb. Planes were interactively
positioned over lower body of mice to segment
microCT image to generate multiple volumes-of-
interests (VOIs). Contours of these VOIs are
illustrated superimposed on representative microCT
image. Segmentation was performed to eliminate
bones from VOIs. This complex irregular object
map was applied to registered microSPECT images
to determine radiotracer activity in each VOI.
developments in imaging strategies to assess angiogenesis
involved using 76Br-labeled biodegradable nanoparticles targeted
at αvβ3 integrin (59). These constructs contain polyethylene
oxide (PEO) chains which allow tuning biodistribution and
clearance rate of the parent targeted nanoparticles by modifying
length and branching of the PEO chains.
All above studies indicate that radiolabeled agents targeted
at molecular markers of the angiogenic process can be a valuable
tool to assess both naturally occurring and therapeutic
angiogenesis. Development of new hybrid scanners combining
anatomical (CT, MRi) and functional (SPECT, PET) imaging
modalities, design of novel targeted probes and reporter gene
systems, as well as availability of interdisciplinary teams
consisting of biologists, chemists, physiologists, physicians and
engineers will result in a tremendous growth in the field of
molecular targeted imaging. All this will allow better
understanding of fundamental biologic processes and
noninvasive monitoring of therapeutic interventions in living
systems with a great potential to translate to clinical practice.
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